The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Multiple Myeloma

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Multiple Myeloma


Psychiatry related information on Multiple Myeloma


High impact information on Multiple Myeloma


Chemical compound and disease context of Multiple Myeloma


Biological context of Multiple Myeloma


Anatomical context of Multiple Myeloma


Gene context of Multiple Myeloma


Analytical, diagnostic and therapeutic context of Multiple Myeloma


  1. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Tagde, A., Singh, H., Kang, M.H., Reynolds, C.P. Blood. Cancer. J. (2014) [Pubmed]
  2. Deep venous thrombosis and thalidomide therapy for multiple myeloma. Osman, K., Comenzo, R., Rajkumar, S.V. N. Engl. J. Med. (2001) [Pubmed]
  3. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. Levy, Y., Tsapis, A., Brouet, J.C. J. Clin. Invest. (1991) [Pubmed]
  4. Tumor-associated antigens in human myeloma. Krueger, R.G., Staneck, L.D., Boehlecke, J.M. J. Natl. Cancer Inst. (1976) [Pubmed]
  5. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. Caligaris-Cappio, F., Bergui, L., Tesio, L., Pizzolo, G., Malavasi, F., Chilosi, M., Campana, D., van Camp, B., Janossy, G. J. Clin. Invest. (1985) [Pubmed]
  6. Metabolism of thyroxine-binding globulin in man. Abnormal rate of synthesis in inherited thyroxine-binding globulin deficiency and excess. Refetoff, S., Fang, V.S., Marshall, J.S., Robin, N.I. J. Clin. Invest. (1976) [Pubmed]
  7. Substance P and histamine induce interleukin-6 expression in human astrocytoma cells by a mechanism involving protein kinase C and nuclear factor-IL-6. Lieb, K., Schaller, H., Bauer, J., Berger, M., Schulze-Osthoff, K., Fiebich, B.L. J. Neurochem. (1998) [Pubmed]
  8. Prednisone mood disorder with associated catatonia. Grigg, J.R. Journal of geriatric psychiatry and neurology. (1989) [Pubmed]
  9. Reversible dementia due to thalidomide therapy for multiple myeloma. Morgan, A.E., Smith, W.K., Levenson, J.L. N. Engl. J. Med. (2003) [Pubmed]
  10. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Iida, S., Rao, P.H., Butler, M., Corradini, P., Boccadoro, M., Klein, B., Chaganti, R.S., Dalla-Favera, R. Nat. Genet. (1997) [Pubmed]
  11. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J., Knight, R.D. N. Engl. J. Med. (1996) [Pubmed]
  12. Erythropoietin treatment of anemia associated with multiple myeloma. Ludwig, H., Fritz, E., Kotzmann, H., Höcker, P., Gisslinger, H., Barnas, U. N. Engl. J. Med. (1990) [Pubmed]
  13. Multiple hematopoietic-cell lineages in multiple myeloma. Shpilberg, O., Modan, M., Modan, B., Ramot, B. N. Engl. J. Med. (1990) [Pubmed]
  14. Effective treatment of advanced multiple myeloma refractory to alkylating agents. Barlogie, B., Smith, L., Alexanian, R. N. Engl. J. Med. (1984) [Pubmed]
  15. Thalidomide in multiple myeloma. Kishi, Y., Oki, Y., Machida, U. N. Engl. J. Med. (2000) [Pubmed]
  16. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. Siris, E.S., Sherman, W.H., Baquiran, D.C., Schlatterer, J.P., Osserman, E.F., Canfield, R.E. N. Engl. J. Med. (1980) [Pubmed]
  17. Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. Kyle, R.A., Jowsey, J., Kelly, P.J., Taves, D.R. N. Engl. J. Med. (1975) [Pubmed]
  18. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. Palmer, R.N., Rick, M.E., Rick, P.D., Zeller, J.A., Gralnick, H.R. N. Engl. J. Med. (1984) [Pubmed]
  19. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Feng, R., Anderson, G., Xiao, G., Elliott, G., Leoni, L., Mapara, M.Y., Roodman, G.D., Lentzsch, S. Blood (2007) [Pubmed]
  20. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Younes, H., Leleu, X., Hatjiharissi, E., Moreau, A.S., Hideshima, T., Richardson, P., Anderson, K.C., Ghobrial, I.M. Clin. Cancer Res. (2007) [Pubmed]
  21. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Song, W., van der Vliet, H.J., Tai, Y.T., Prabhala, R., Wang, R., Podar, K., Catley, L., Shammas, M.A., Anderson, K.C., Balk, S.P., Exley, M.A., Munshi, N.C. Clin. Cancer Res. (2008) [Pubmed]
  22. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Fabre, C., Mimura, N., Bobb, K., Kong, S.Y., Gorgun, G., Cirstea, D., Hu, Y., Minami, J., Ohguchi, H., Zhang, J., Meshulam, J., Carrasco, R.D., Tai, Y.T., Richardson, P.G., Hideshima, T., Anderson, K.C. Clin. Cancer Res. (2012) [Pubmed]
  23. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Chauhan, D., Ray, A., Viktorsson, K., Spira, J., Paba-Prada, C., Munshi, N., Richardson, P., Lewensohn, R., Anderson, K.C. Clin. Cancer Res. (2013) [Pubmed]
  24. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Görgün, G., Samur, M.K., Cowens, K.B., Paula, S., Bianchi, G., Anderson, J.E., White, R.E., Singh, A., Ohguchi, H., Suzuki, R., Kikuchi, S., Harada, T., Hideshima, T., Tai, Y.T., Laubach, J.P., Raje, N., Magrangeas, F., Minvielle, S., Avet-Loiseau, H., Munshi, N.C., Dorfman, D.M., Richardson, P.G., Anderson, K.C. Clin. Cancer Res. (2015) [Pubmed]
  25. Markers of multiple hematopoietic-cell lineages in multiple myeloma. Epstein, J., Xiao, H.Q., He, X.Y. N. Engl. J. Med. (1990) [Pubmed]
  26. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Catlett-Falcone, R., Landowski, T.H., Oshiro, M.M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J.L., Nuñez, G., Dalton, W.S., Jove, R. Immunity (1999) [Pubmed]
  27. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Chauhan, D., Catley, L., Hideshima, T., Li, G., Leblanc, R., Gupta, D., Sattler, M., Richardson, P., Schlossman, R.L., Podar, K., Weller, E., Munshi, N., Anderson, K.C. Blood (2002) [Pubmed]
  28. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Galm, O., Yoshikawa, H., Esteller, M., Osieka, R., Herman, J.G. Blood (2003) [Pubmed]
  29. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Ernst, T.J., Gazdar, A., Ritz, J., Shipp, M.A. Blood (1988) [Pubmed]
  30. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. Zhang, X.G., Gu, J.J., Lu, Z.Y., Yasukawa, K., Yancopoulos, G.D., Turner, K., Shoyab, M., Taga, T., Kishimoto, T., Bataille, R. J. Exp. Med. (1994) [Pubmed]
  31. Cancer incidence among Danish Thorotrast-exposed patients. Andersson, M., Storm, H.H. J. Natl. Cancer Inst. (1992) [Pubmed]
  32. Proportionate mortality study of workers in the grain industry. Alavanja, M.C., Rush, G.A., Stewart, P., Blair, A. J. Natl. Cancer Inst. (1987) [Pubmed]
  33. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Tjin, E.P., Groen, R.W., Vogelzang, I., Derksen, P.W., Klok, M.D., Meijer, H.P., van Eeden, S., Pals, S.T., Spaargaren, M. Blood (2006) [Pubmed]
  34. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Choi, C., Witzens, M., Bucur, M., Feuerer, M., Sommerfeldt, N., Trojan, A., Ho, A., Schirrmacher, V., Goldschmidt, H., Beckhove, P. Blood (2005) [Pubmed]
  35. Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Wang, L.H., Yang, X.Y., Zhang, X., Huang, J., Hou, J., Li, J., Xiong, H., Mihalic, K., Zhu, H., Xiao, W., Farrar, W.L. Immunity (2004) [Pubmed]
  36. Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. Chauhan, D., Kharbanda, S.M., Ogata, A., Urashima, M., Frank, D., Malik, N., Kufe, D.W., Anderson, K.C. J. Exp. Med. (1995) [Pubmed]
  37. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Bergsagel, P.L., Kuehl, W.M., Zhan, F., Sawyer, J., Barlogie, B., Shaughnessy, J. Blood (2005) [Pubmed]
  38. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Nojima, M., Maruyama, R., Yasui, H., Suzuki, H., Maruyama, Y., Tarasawa, I., Sasaki, Y., Asaoku, H., Sakai, H., Hayashi, T., Mori, M., Imai, K., Tokino, T., Ishida, T., Toyota, M., Shinomura, Y. Clin. Cancer Res. (2009) [Pubmed]
  39. Carcinoma of the breast. Occurence after treatment with melphalan for multiple myeloma. Bell, R., Sullivan, J.R., Fone, D.J., Hurley, T.H. JAMA (1976) [Pubmed]
  40. Cytoplasmic immunoglobulin content in multiple myeloma. Barlogie, B., Alexanian, R., Pershouse, M., Smallwood, L., Smith, L. J. Clin. Invest. (1985) [Pubmed]
  41. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Sonneveld, P., Durie, B.G., Lokhorst, H.M., Marie, J.P., Solbu, G., Suciu, S., Zittoun, R., Löwenberg, B., Nooter, K. Lancet (1992) [Pubmed]
  42. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Barlogie, B., Hall, R., Zander, A., Dicke, K., Alexanian, R. Blood (1986) [Pubmed]
  43. Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. Cohen, H.J., Silberman, H.R., Larsen, W.E., Johnson, L., Bartolucci, A.A., Durant, J.R. Blood (1979) [Pubmed]
WikiGenes - Universities